APA (7th ed.) Citation

Y, Z., L, B., H, Z., H, T., C, P., & J, W. (2025). ASO Author Reflections: Limited Survival Benefit from Neoadjuvant Chemotherapy in ER+/HER2- Breast Cancer. Annals of surgical oncology, 32(9), 6687. https://doi.org/10.1245/s10434-025-17408-4

Chicago Style (17th ed.) Citation

Y, Zou, Bian L, Zhang H, Tang H, Peng C, and Wang J. "ASO Author Reflections: Limited Survival Benefit from Neoadjuvant Chemotherapy in ER+/HER2- Breast Cancer." Annals of Surgical Oncology 32, no. 9 (2025): 6687. https://doi.org/10.1245/s10434-025-17408-4.

MLA (9th ed.) Citation

Y, Zou, et al. "ASO Author Reflections: Limited Survival Benefit from Neoadjuvant Chemotherapy in ER+/HER2- Breast Cancer." Annals of Surgical Oncology, vol. 32, no. 9, 2025, p. 6687, https://doi.org/10.1245/s10434-025-17408-4.